BP003055: Biotinylated Recombinant SARS-CoV-2 Spike S1-His-Avi Protein (Spike Protein S1 Subunit)
Source: mammalian cells.
Activity: Immobilized biotinylated recombinant SARS-CoV-2 Spike S1-His-Avi protein at 1 ug/ml (100 ul/well). Dose response curve for the recombinant human ACE2-Fc fusion protein with the EC50 of 81 ng/ml determined by ELISA.
Purity: > 95% by PAGE under reduced condition, and SEC-HPLC.BP003051: Biotinylated Recombinant SARS-CoV-2 Spike RBD-His-Avi (S1 RBD)
Source: mammalian cells.
Activity: Immobilized biotinylated recombinant SARS-CoV-2 Spike RBD-His-Avi protein at 1 ug/ml (100 ul/well). Dose response curve for the recombinant human ACE2-Fc fusion protein with the EC50 of 100 ng/ml determined by ELISA.
Purity: > 95% by PAGE under reduced condition, and SEC-HPLC.BP003082: Recombinant Human CD319 / CRACC / SLAMF7 Protein
Source: mammalian cells.
Purity: > 95% by Bis-Tris PAGE and HPLC.BP003082: Recombinant Human CD319 / CRACC / SLAMF7 Protein
Source: mammalian cells.
Purity: > 95% by Bis-Tris PAGE and HPLC.BP002388-Z53: Recombinant Human Cellular tumor antigen p53 (p53) Protein
Source: Baculovirus, SF9 insect cells-derived.
Bioactivity test: 1 unit equals 1 nanogram of purified protein. 10 unit is sufficient for a gel mobility shift assay in a 20 ul reaction; 50 units are sufficient for reconstituted transcription assay and 100 units are sufficient for a protein-protein interaction assay.
Purity: > 95%, by SDS-PAGE.
Endotoxin Level: < 1.0 EU per 1 ug of the protein by the LAL method.BP001577-K0108: Recombinant Human PAK7 Kinase Domain, aka PAK5 (PAK7KD) Enzyme
Source: E. coli-derived.
Specific activity: 4,199 pmoles/min/ug. Analysis of enzymatic activity was performed according to the Zlyte assay protocol (Invitrogen).
Applications: Enzymatic studies, inhibitor screen, and selectivity profiling; High concentration available for crystallization.C015: Ovidrel Biosimilar Stable Cell Line (CHO)
The yield of Ovidrel biosimilar from the CHO stable cell line was above 250 mg/L in a 15 liter manufacturing.
BP000145-GD20: Recombinant Human Interleukin-2 (IL-2) Protein
Source: E. coli-derived.
The ED50 as determined by the dose-dependant stimulation of murine CTLL-2 cells is less than 0.1 ng/ml, corresponding to a Specific Activity of 1.0 x 10^7 IU/ mg.
Purity: > 95% by SEC-HPLC and reducing SDS-PAGE.
Endotoxin: < 0.1 ng/ug (1 IEU/ug).BP000134-GD21: Recombinant Human Interleukin-11 (IL-11) Protein
Source: P. Pichia-derived.
The ED50 as determined by the dose-dependant stimulation of the proliferation of murine 7TD1 was found to be less than 0.2 ng/ml, corresponding to a Specific Activity of 8.0 x 10^6 IU/mg.
Purity: > 95% by RP-HPLC and reducing SDS-PAGE.
Endotoxin: < 0.1 ng/ug (1 EU/ug).BP000082-GD27: Recombinant Human IFN alpha 2a (IFNA2) Protein
Source: E. coli-derived.
The specific activity as determined by a viral resistance assay using VSV-WISH cells was found to be 1.0 x 10^8 IU/mg.
Purity: > 95% by RP-HPLC and reducing SDS-PAGE.
Endotoxin: < 0.1 ng/ug (1 EU/ug).